01 7YAZ/Yasim/Yasminelle
02 1YAZTM/YasimTM/YasminelleTM
03 2Yaz/Yasim/Yasminelle
Main Therapeutic Indication : Urology
Currency : USD
2020 Revenue in Millions : 810
2019 Revenue in Millions : 824
Growth (%) : -2
Main Therapeutic Indication : Urology
Currency : USD
2021 Revenue in Millions : 815
2020 Revenue in Millions : 810
Growth (%) : 10
Main Therapeutic Indication : Women's Health
Currency : USD
2022 Revenue in Millions : 830
2021 Revenue in Millions : 815
Growth (%) : 2
Main Therapeutic Indication : Women's Health
Currency : USD
2023 Revenue in Millions : 727
2022 Revenue in Millions : 830
Growth (%) : -15
Drospirenone and Ethinyl Estradiol
Main Therapeutic Indication : Sexual Health
Currency : USD
2015 Revenue in Millions : 845
2014 Revenue in Millions : 777
Growth (%) : -8%
Drospirenone and Ethinyl Estradiol
Main Therapeutic Indication : Sexual Health
Currency : USD
2014 Revenue in Millions : -10.00%
2013 Revenue in Millions :
Growth (%) :
Drospirenone and Ethinyl Estradiol
Main Therapeutic Indication : Sexual Health
Currency : USD
2017 Revenue in Millions : 804
2016 Revenue in Millions : 841
Growth (%) : -4
Drospirenone And Ethinyl Estradiol
Main Therapeutic Indication : Sexual Health
Currency : USD
2016 Revenue in Millions : 719
2015 Revenue in Millions : 748
Growth (%) : -4
Drospirenone And Ethinyl Estradiol
Main Therapeutic Indication : Sexual Health
Currency : USD
2018 Revenue in Millions : 722
2017 Revenue in Millions : 732
Growth (%) : -1%
Main Therapeutic Indication : Urology
Currency : USD
2019 Revenue in Millions : 742
2018 Revenue in Millions : 697
Growth (%) : 7
LOOKING FOR A SUPPLIER?